Press Releases

Press Releases

Stay updated on the latest Vistagen News and get the details about important events, public financial reports, and our product pipeline updates.

SOUTH SAN FRANCISCO, Calif., March 30, 2016 /PRNewswire/ --  VistaGen Therapeutics, Inc.  (OTCQB: VSTA) (VistaGen or the Company), a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving
- Sanjay Mathew, M.D., expert in the psychopharmacological management of depressive and anxiety disorders, appointed as Board member - - Thomas Laughren, M.D., expert in the safety and efficacy of psychiatric drugs with nearly 30 years of experience at the FDA, appointed as Board member - -
New Licenses Expand Core Drug Rescue Programs and Collaborative Regenerative Medicine Opportunities Related to Heart Disease, Liver Disease and Osteoarthritis SOUTH SAN FRANCISCO, Calif., Dec. 23, 2015 /PRNewswire/ -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical
SAN FRANCISCO, Nov. 3, 2015 /PRNewswire/ -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat depression, cancer and diseases and disorders involving the central nervous system (CNS), today
SAN FRANCISCO, Oct. 7, 2015 /PRNewswire/ -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat depression, cancer and diseases and disorders involving the central nervous system (CNS), today
Pre-clinical Study Results Show Equal Efficacy and Improved Safety Profile Compared with Ketamine SOUTH SAN FRANCISCO, Calif., Sept. 16, 2015 /PRNewswire/ -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company committed to developing and commercializing novel
Phase 2 Clinical Study in Major Depressive Disorder Expected to Commence at NIH in 3Q 2015 SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 07/01/15 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative product
Similar to Ketamine, AV-101 Has a Fundamentally Novel Mechanism of Action Compared to All Approved Antidepressants SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 02/17/15 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company developing innovative medicine for
Yale Depression Expert to Advise on Late-Stage Development of Orally-Active AV-101 for Major Depressive Disorder SAN FRANCISCO, CA -- (Marketwired) -- 02/05/15 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company developing innovative medicine for depression and
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/17/14 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company focused on innovative medicine for depression, cancer and diseases and disorders involving the central nervous system (CNS), has signed a Letter of Intent to